BIOMAT Database Logo BIOMAT Database Logo

[Neutralization of foot-and-mouth disease virus O1 Campos by antibodies induced by a synthetic peptide]. 1988

M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria (INTA), Argentina.

Foot-and-Mouth disease virus (FMDV), contains a positive single-stranded RNA enclosed in a protein capsid. Previous studies have shown that a synthetic peptide located at the carboxyterminal end of VP1 of FMDV strain O1 Kaufbeuren (O1K) at the amino acid positions 144-159, and coupled to KLH was able to elicit high titers of neutralizing antibodies in guinea pigs and protected them against challenge with the homologous virus (8, 15). FMDV strain O1 Campos (O1 Ca) has a similar amino acid sequence to O1K, differing in amino acid 144 (leucin instead valine). We report that the O1K synthetic peptide 144-159 protects adult mice against challenge with FMDV O1Ca when the peptide is coupled to KLH with glutaraldehyde as coupling agent (Table 2) whereas protection is very low when other carrier proteins are used.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D005537 Aphthovirus A genus of the family PICORNAVIRIDAE infecting mainly cloven-hoofed animals. They cause vesicular lesions and upper respiratory tract infections. FOOT AND MOUTH DISEASE VIRUS is the type species. Equine rhinitis A virus,Equine rhinovirus 1,Aphthoviruses
D006433 Hemocyanins Metalloproteins that function as oxygen transport proteins in the HEMOLYMPH of MOLLUSKS and ARTHROPODS. They are characterized by two copper atoms, coordinated with HISTIDINE residues, that reversibly bind a single oxygen molecule; they do not contain HEME groups. Hemocyanin,alpha-Haemocyanin,alpha-Hemocyanin,alpha-Hemocyanins,alpha Haemocyanin,alpha Hemocyanin,alpha Hemocyanins
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
January 1988, Virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
October 1986, The Journal of general virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Full length nucleotide sequence of foot-and-mouth disease virus strain O1 Campos/Bra/58. Brief report.
November 2002, Archives of virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Synthetic peptide vaccines: foot-and-mouth disease virus as a model.
January 1999, Developments in biological standardization,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Phenotypic and functional characterization of mouse attenuated and virulent variants of foot-and-mouth disease virus type O1 Campos.
April 1993, Virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Role of arginine-56 within the structural protein VP3 of foot-and-mouth disease virus (FMDV) O1 Campos in virus virulence.
January 2012, Virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.
February 2011, Vaccine,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Localization of a neutralization epitope of foot-and-mouth disease virus using neutralizing monoclonal antibodies.
September 1984, The Journal of general virology,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies.
June 2022, Protein & cell,
M Piccone, and G Zuloaga, and F Marcovecchio, and A Arese, and J C Monesiglio, and E L Palma
Synthetic peptide vaccines against foot and mouth disease.
December 1986, Vaccine,
Copied contents to your clipboard!